Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.46 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14047561 | 0.90 | DHODH (0.52) | PTGDR2DHODHPIK3CDTACR3 | |
| SCHEMBL19344383 | 0.88 | PIK3CD (0.40) | PTGDR2DHODHPIK3CDCYP1A2CYP3A4 | |
| SCHEMBL14047567 | 0.83 | CYP11B2 (0.48) | DHODH | |
| SCHEMBL19331478 | 0.83 | TAAR1 (0.47) | PTGDR2PIK3CDTBXA2RPTGDRTACR3 | |
| SCHEMBL20081260 | 0.80 | PDE10A (0.51) | DHODHPIK3CDCYP1A2CYP3A4USP2 | |
| SCHEMBL19331477 | 0.79 | MAP4K4 (0.45) | PTGDR2PIK3CDTACR3CYP1A2CYP3A4 | |
| SCHEMBL10285582 | 0.78 | PTGDR2 (0.40) | PTGDR2TBXA2RPTGDRCYP1A2CYP3A4 | |
| SCHEMBL20061322 | 0.77 | ADORA2A (0.40) | PTGDR2DHODHPIK3CDCYP1A2CYP3A4 | |
| SCHEMBL20067861 | 0.77 | PIK3CD (0.57) | DHODHPIK3CDTACR3CYP1A2CYP3A4 | |
| SCHEMBL19344369 | 0.76 | KDM4E (0.48) | DHODHPIK3CDALDH1A1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3400227-B1 | QUINOLINE ANALOGS AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | HANGZHOU ZHENGXIANG PHARMACEUTICALS CO LTD (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-20210046075-A1 | QUINOLINE ANALOGS AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
| US-10792283-B2 | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors | HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2020-10-06 | — | — | US | disclosed |
| EP-3312175-B1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RES INST CHEMICAL TECH (KR) | 2020-07-22 | — | — | EP | disclosed |
| EP-3312175-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2018-04-25 | — | — | EP | disclosed |
| WO-2017155741-A1 | QUINOLINE ANALOGS AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | ZHEJIANG VIMGREEN PHARMA LTD. (CN) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10792283-B2 | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors | PIK3CD, PI4KB, PIK3CA | PTGDR2 2672/4885DHODH 2633/4885PIK3CD 1/4885 |
| US-20210046075-A1 | QUINOLINE ANALOGS AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CD, PI4KB, PIK3CA | PTGDR2 2672/4885DHODH 2633/4885PIK3CD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.